PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Title only   |   Print    Next page > 
     
New Study Confirms Capsugel® Enprotect® Capsules Deliver Robust Gastric Integrity Under Both Fasted and Fed Conditions
SEOUL, South Korea , Aug. 14, 2026 /PRNewswire/ -- Enteric capsules are widely used to protect acid-sensitive compounds and to delay drug release until intestinal entry. However, evidence supporting ...
2026-08-17T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
DayOne Launches Singapore's First Biological Data Center Prototype with Cortical Labs and NUS Medicine
SINGAPORE , Aug. 17, 2026 /PRNewswire/ -- DayOne Data Centers Limited ("DayOne"), a Singapore-headquartered global digital infrastructure platform, today launched Singapore's first Biological ...
2026-08-17T    Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics
NANJING, China and SINGAPORE , Aug. 14, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio) today announced the completion of its acquisition of MediSix Therapeutics ("MediSix"), a Singapore-based ...
2026-08-14T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
SK bioscience Advances Development of Next-Generation Infectious Disease Prevention Platform with Global Phase 1b CTA Submission for RSV Preventive Antibody Candidate
Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months Company expands its global portfolio beyond vaccines into antibody-based preventive ...
2026-08-14T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial
SHANGHAI , Aug. 14, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir (AK0529) ...
2026-08-14T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass. , Aug. 13, 2026 /PRNewswire/ -- Innorna, a clinical-stage biotech company advancing RNA medicines, today announced that it has been nominated ...
2026-08-13T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Rhein Laser Unveils CELIORA®, a New Generation of Intelligent Red Light Therapy Beds
Five Wavelengths and 88,000 LED Chips Deliver the Industry's First Continuous, Dark-Line-Free Full-Body Red-Light Coverage ...
2026-08-13T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Coreline Soft and Optellum announce intent to collaborate to advance AI across the lung cancer pathway
Proposed collaboration would make Coreline Soft's FDA-cleared lung nodule detection capability available through Optellum's LungOS ® platform ...
2026-08-13T    Computer Software   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
/DISREGARD RELEASE: IASO Bio/
We are advised by IASO Bio that journalists and other readers should disregard the news release, IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics, issued ...
2026-08-13T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Accro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in Barcelona
NEW YORK and SUZHOU, China , Aug. 13, 2026 /PRNewswire/ -- Accro Bioscience, a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, ...
2026-08-13T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.